Myriad Submits sPMA For BRACAnalysis CDx As A Companion Diagnostic For Lynparza In Metastatic Castration-resistant Prostate Cancer

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and precision medicine, announced today that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug

Benzinga · 01/21/2020 12:05

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and precision medicine, announced today that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its BRACAnalysis® CDx test as a companion diagnostic to AstraZeneca’s (NYSE:AZN) and Merck’s PARP inhibitor Lynparza® (olaparib) for men with metastatic castration-resistant prostate cancer.